Testing a drug called C5252 in people with a tumor inside the skull
Official title: A Phase I/IIa Study of C5252 in Patients With Intracranial Tumor
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on .
The short version
This trial is testing whether a drug called C5252 is safe for people with a brain tumor.
Read our full plain-language summary
What the trial team says
This study includes phase I dose escalation part and phase IIa dose expansion part. The goal of this clinical trial is to learn if C5252 treatment is safe and well tolerated in patients with intracranial tumor and to learn preliminary efficacy of C5252. In this study, participants will be given single or multiple doses of C5252 according to protocol followed by toxicity observation, safety follow-up and long-term follow-up.
Key facts
- Registry number
- NCT07243340
- Stage of testing
- Phase 1/Phase 2
- Conditions studied
- Glioma, Malignant
Where it is running
This trial lists 1 site.
-
Tianjin Municipality
- Tianjin Medical University Cancer Institute & Hospital (Tianjin)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.